Soleno Therapeutics (SLNO) Net Income towards Common Stockholders: 2013-2017
Historic Net Income towards Common Stockholders for Soleno Therapeutics (SLNO) over the last 4 years, with Dec 2017 value amounting to -$544,000.
- Soleno Therapeutics' Net Income towards Common Stockholders rose 79.18% to -$544,000 in Q4 2017 from the same period last year, while for Dec 2017 it was -$3.6 million, marking a year-over-year increase of 75.21%. This contributed to the annual value of -$175.8 million for FY2024, which is 353.15% down from last year.
- As of Q4 2017, Soleno Therapeutics' Net Income towards Common Stockholders stood at -$544,000, which was up 57.96% from -$1.3 million recorded in Q3 2017.
- In the past 5 years, Soleno Therapeutics' Net Income towards Common Stockholders registered a high of -$544,000 during Q4 2017, and its lowest value of -$6.4 million during Q3 2016.
- Its 3-year average for Net Income towards Common Stockholders is -$2.5 million, with a median of -$2.5 million in 2015.
- As far as peak fluctuations go, Soleno Therapeutics' Net Income towards Common Stockholders tumbled by 379.25% in 2014, and later surged by 80.25% in 2017.
- Quarterly analysis of 5 years shows Soleno Therapeutics' Net Income towards Common Stockholders stood at -$869,278 in 2013, then tumbled by 379.25% to -$4.2 million in 2014, then spiked by 31.72% to -$2.8 million in 2015, then rose by 8.13% to -$2.6 million in 2016, then spiked by 79.18% to -$544,000 in 2017.
- Its last three reported values are -$544,000 in Q4 2017, -$1.3 million for Q3 2017, and -$913,000 during Q2 2017.